257 results match your criteria: "Osteoncology & Rare Tumors Center[Affiliation]"

Background: The prognosis of patients with Relapsed/Refractory Osteosarcoma (R/R OS) remains dismal without an agreement on systemic therapy. The use of High-Dose Ifosfamide (14 g/sqm) with an external pump in outpatient setting (14-IFO) in R/R OS patients is limited. This study represents the first retrospective cohort analysis focused on evaluating the activity and toxicity of 14-IFO in this setting.

View Article and Find Full Text PDF

The emerging role of intra-tumoral bacteria.

J Gastrointest Oncol

April 2024

Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

View Article and Find Full Text PDF

A reduction in tumor volume exceeding 65% predicts a good histological response to neoadjuvant chemotherapy in patients with Ewing sarcoma.

Skeletal Radiol

December 2024

Clinica Ortopedica E Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy.

Article Synopsis
  • The study aimed to find a cutoff for predicting histological response in Ewing sarcoma based on tumor volume changes after chemotherapy.
  • Out of 184 patients analyzed, a reduction of over 65% in tumor volume was identified as an optimal threshold for a good histological response, with a 45% response rate of necrosis.
  • While tumor volume reduction itself did not influence survival, poor histological responses were linked to decreased relapse-free survival, indicating potential benefits from more aggressive treatments for at-risk patients.
View Article and Find Full Text PDF

Histological and imaging features of myoepithelial carcinoma of the bone and soft tissue.

Skeletal Radiol

December 2024

Clinica Ortopedica e Traumatologica III a Prevalente Indirizzo Oncologico, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy.

Article Synopsis
  • The study aimed to analyze the histological and imaging characteristics of myoepithelial carcinoma in bone and soft tissue, examining data from 22 patients over time.
  • Results showed that a significant number of patients experienced local recurrence (36.3%) and distant metastasis (50.0%), with severe cytological changes and vascular invasion being noted in many cases.
  • The findings suggest that understanding these histological and imaging features could help identify the aggressive nature of myoepithelial carcinoma, highlighting its high risk for recurrence and metastasis.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to determine the best treatment sequence for patients with advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) by analyzing data on progression-free survival (PFS) and overall survival (OS).
  • In total, 201 patients were examined, revealing that those with grade 1 pNETs, prior tumor surgery, and those treated with radioligand therapy (RLT) experienced significantly longer PFS.
  • The findings suggest that RLT is associated with better PFS than other treatments, and that a treatment sequence starting with somatostatin analogs (SSA) followed by RLT leads to improved outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • Tissue-engineered implants for bone regeneration need to consider their ability to mineralize and develop blood vessels, with design shapes impacting these features.
  • NEST3D printing was used to create various scaffold designs (logpile, Voronoi, trabecular) from polycaprolactone to analyze their mechanical stiffness and vascularization potential.
  • Results indicated that while gelatin methacryloyl did not facilitate blood vessel infiltration on its own, the polycaprolactone scaffolds supported tissue and vessel growth, with the trabecular design yielding the highest mineralization.
View Article and Find Full Text PDF

Purpose: Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy; the prevention and management of possible side effects, including renal toxicity, hypocalcaemia, and medication-related osteonecrosis of the jaw (MRONJ).

Methods: Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast cancer, prostate cancer, and other solid tumors. Prevention and management of side effects were also investigated.

View Article and Find Full Text PDF

Five-year glioblastoma (GBM) survivors (LTS) are the minority of the isocitrate dehydrogenase (IDH)-wild-type GBM patients, and their molecular fingerprint is still largely unexplored. This multicenter retrospective study analyzed a large LTS-GBM cohort from nine Italian institutions and molecularly characterized a subgroup of patients by mutation, DNA methylation (DNAm) and copy number variation (CNV) profiling, comparing it to standard survival GBM. Mutation scan allowed the identification of pathogenic variants in most cases, showing a similar mutational spectrum in both groups, and highlighted TP53 as the most commonly mutated gene in the LTS group.

View Article and Find Full Text PDF

Chronic exposure to ultraviolet (UV) radiation is known to induce the formation of DNA photo-adducts, including cyclobutane pyrimidine dimers (CPDs) and Dewar valence derivatives (DVs). While CPDs usually occur at higher frequency than DVs, recent studies have shown that the latter display superior selectivity and significant stability in interaction with the human DNA/topoisomerase 1 complex (TOP1). With the aim to deeply investigate the mechanism of interaction of DVs with TOP1, we report here four all-atom molecular dynamic simulations spanning one microsecond.

View Article and Find Full Text PDF

Editorial: The immune infiltrate as a paradigm model to study the biology and novel therapeutic approaches in sarcomas.

Front Endocrinol (Lausanne)

December 2023

Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

View Article and Find Full Text PDF

Methotrexate (MTX) is one of the most important drugs included in the first-line protocols to treat high-grade osteosarcoma (HGOS). Although several polymorphisms have been reported to be associated with drug response or MTX-related toxicity in pharmacogenetic studies, their role in the development of MTX resistance in HGOS is still unclear. Therefore, in this study, 22 single nucleotide polymorphisms (SNPs) in 4 genes of the folate metabolism, 7 MTX transporter genes, and 2 SNPs of the tumor protein p53 () gene were investigated using a custom multimodal-targeted next-generation sequencing (mmNGS) approach in 8 MTX-resistant and 12 MTX-sensitive human HGOS cell lines.

View Article and Find Full Text PDF

A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models.

BMC Cancer

December 2023

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136, Bologna, Italy.

Article Synopsis
  • Myxofibrosarcoma is a rare and aggressive soft tissue cancer that often recurs and becomes more severe with each recurrence, posing challenges for patients and clinicians alike.
  • The study introduces a new cell line (MF-R 3) derived from a myxofibrosarcoma patient, which was thoroughly characterized using various biological tests to evaluate its tumor properties.
  • The MF-R 3 cell line exhibits similar characteristics to the original tumor and has shown promising sensitivity to anthracycline drugs, making it a valuable model for further research and drug testing.
View Article and Find Full Text PDF

Alveolar soft part sarcoma (ASPS) is an extremely rare and aggressive soft-tissue sarcoma (STS) subtype with poor prognosis and limited response to radiation therapy and chemotherapy. Prompt recognition and referral to sarcoma centers for appropriate management are crucial for patients' survival. The purpose of this study was to report ASPS pre-treatment imaging features and to examine the existing literature on this topic.

View Article and Find Full Text PDF

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Cancers (Basel)

October 2023

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Myxofibrosarcoma (MFS) is a malignant soft tissue sarcoma (STS) that originates in the body's connective tissues. It is characterized by the presence of myxoid (gel-like) and fibrous components and typically affects patients after the fifth decade of life. Considering the ongoing trend of increasing lifespans across many nations, MFS is likely to become the most common musculoskeletal sarcoma in the future.

View Article and Find Full Text PDF

Objective: Glucocorticoid-induced osteoporosis (GIOP) is a common cause of secondary osteoporosis. However, glucocorticoid requiring diseases pose a risk themselves for fracture. The aim of the present study was to determine the risk of fracture associated with variety of glucocorticoid requiring diseases independently from glucocorticoid use and other risk factors for osteoporosis.

View Article and Find Full Text PDF

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.

Front Oncol

October 2023

Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies. Entrectinib and larotrectinib obtained unprecedented response rates in patients with cancer harboring NTRK rearrangements. This evidence recently led to the agnostic approval of these drugs, and evidence (confirmation) of their activity in a broader disease setting is emerging.

View Article and Find Full Text PDF

Myoepithelial carcinoma of soft tissues and bone.

Eur J Cancer

November 2023

Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address:

Article Synopsis
  • The study investigates the treatment outcomes and factors influencing myoepithelial carcinoma of soft tissue and bone based on 33 patients treated between 1998 and 2015.
  • The research found that a significant number of patients experienced local recurrences and metastases, with a five-year survival rate of 62.6% for those with localized tumors.
  • The authors emphasize the need for multidisciplinary treatment approaches, as current chemotherapy options do not significantly improve outcomes for patients with metastatic disease.
View Article and Find Full Text PDF

Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.

EBioMedicine

November 2023

Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address:

Background: Malignant peripheral nerve sheath tumour (MPNST) is an aggressive orphan disease commonly affecting adolescents or young adults. Current knowledge of molecular tumour biology has been insufficient for development of rational treatment strategies. We aimed to discover molecular subtypes of potential clinical relevance.

View Article and Find Full Text PDF

High-grade transformation of a polymorphous adenocarcinoma of the salivary gland: a case report and review of the literature.

Front Oncol

September 2023

Preclinic and Osteoncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Background: Polymorphous adenocarcinoma (PAC) represents the second most widespread neoplasm of the minor salivary glands. These tumors rarely develop a histological progression from low-grade to high-grade malignancy, named "high-grade transformation" (HGT). Only nine cases are described in literature.

View Article and Find Full Text PDF

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.

BMC Cancer

September 2023

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy.

Background: Heterozygous isocitrate dehydrogenase (IDH) mutations occur in about half of conventional central bone chondrosarcomas (CCBC). Aim of this study was to assess the frequency and prognostic impact of IDH mutations in high grade CCBC patients.

Methods: 64 patients with G2 and G3 CCBC were included.

View Article and Find Full Text PDF

A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?

Cancer Treat Rev

November 2023

Department of Oncology for Child and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France; National Institute for Health and Medical Research (INSERM) U1015, BiiOSTeam, Gustave Roussy Institute, Villejuif, France. Electronic address:

Background/objective: To analyze changes in recurrent/refractory osteosarcoma phase II trials over time to inform future trials in this population with poor prognosis.

Methods: A systematic review of trials registered on trial registries between 01/01/2017-14/02/2022. Comparison of 98 trials identified between 2003 and 2016.

View Article and Find Full Text PDF

Background: Immunotherapy has recently been incorporated into the spectrum of biliary tract cancer (BTC) treatment. The identification of predictive response biomarkers is essential in order to identify those patients who may benefit most from this novel treatment option. Here, we propose a systematic literature review and a meta-analysis of PD-1, PD-L1, and other immune-related biomarker expression levels in patients with BTC.

View Article and Find Full Text PDF

Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.

Cancer Epidemiol

October 2024

Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA. Electronic address:

Introduction: Several studies have linked increased risk of osteosarcoma with tall stature, high birthweight, and early puberty, although evidence is inconsistent. We used genetic risk scores (GRS) based on established genetic loci for these traits and evaluated associations between genetically inferred birthweight, height, and puberty timing with osteosarcoma.

Methods: Using genotype data from two genome-wide association studies, totaling 1039 cases and 2923 controls of European ancestry, association analyses were conducted using logistic regression for each study and meta-analyzed to estimate pooled odds ratios (ORs) and 95% confidence intervals (CIs).

View Article and Find Full Text PDF

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.

J Neurooncol

August 2023

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy.

Purpose: The aims of our retrospective study investigated the role of immune system in glioblastoma (GBM), which is the most aggressive primary brain tumor in adults characterized by a poor prognosis. The recurrence rate remains high, probably due to "immune-desert" tumor microenvironment (TME) making GBM hidden from the anti-tumoral immune clearance. Considering this, we aimed to create a panel of prognostic markers from blood and tumor tissue correlating with overall survival (OS) and progression-free survival (PFS).

View Article and Find Full Text PDF